• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Feb 1, 2010; 120(2): 472–484.
Published online Jan 11, 2010. doi:  10.1172/JCI39434
PMCID: PMC2810076

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

Abstract

PDGFR is an important target for novel anticancer therapeutics because it is overexpressed in a wide variety of malignancies. Recently, however, several anticancer drugs that inhibit PDGFR signaling have been associated with clinical heart failure. Understanding this effect of PDGFR inhibitors has been difficult because the role of PDGFR signaling in the heart remains largely unexplored. As described herein, we have found that PDGFR-β expression and activation increase dramatically in the hearts of mice exposed to load-induced cardiac stress. In mice in which Pdgfrb was knocked out in the heart in development or in adulthood, exposure to load-induced stress resulted in cardiac dysfunction and heart failure. Mechanistically, we showed that cardiomyocyte PDGFR-β signaling plays a vital role in stress-induced cardiac angiogenesis. Specifically, we demonstrated that cardiomyocyte PDGFR-β was an essential upstream regulator of the stress-induced paracrine angiogenic capacity (the angiogenic potential) of cardiomyocytes. These results demonstrate that cardiomyocyte PDGFR-β is a regulator of the compensatory cardiac response to pressure overload–induced stress. Furthermore, our findings may provide insights into the mechanism of cardiotoxicity due to anticancer PDGFR inhibitors.

Introduction

PDGF receptors and/or ligands are overexpressed in a wide variety of malignancies (14). In the past decade, a number of inhibitors of receptor tyrosine kinases (RTKs) whose targets include PDGFR have emerged as agents with remarkable efficacy in the treatment of human cancers (57). However, several of these agents have been linked to the development of cardiomyopathy in subsets of treated patients.

Recent reports indicate that the anticancer agent sunitinib, whose targets include PDGFR, causes cardiac dysfunction in up to 19% of treated patients (8), and we and others have reported the development of clinical heart failure in subsets of sunitinib-treated patients (810). Sorafenib, another RTK inhibitor that targets PDGFR, was recently associated with myocardial damage and cardiac dysfunction in renal cell carcinoma patients (10). In addition, imatinib, whose targets include PDGFR in addition to Abl kinase, has been linked to the development of cardiomyopathy (11), although this appears to be an infrequent clinical occurrence (12). Importantly, both sunitinib and sorafenib lead to the development of subacute, severe hypertension in substantial numbers of patients (8, 13), while imatinib rarely causes hypertension.

Linking the incidence of cardiomyopathy associated with anticancer PDGFR inhibitors with the relative incidences of hypertension associated with these drugs led us to hypothesize that PDGFR signaling in the heart may play a key role in the cardiac response to vascular stress such as hypertension. However, little is known regarding the role of PDGFR signaling in adult cardiomyocytes. We show here that cardiomyocyte PDGFR-β expression and activation rise dramatically in response to pressure overload–induced stress. Furthermore, we show that knockout of PDGFR-β in the cardiomyocyte results in cardiac dysfunction, heart failure, and a marked defect in stress-induced cardiac angiogenesis. Mechanistically, we demonstrate that PDGFR-β is an essential regulator of the paracrine angiogenic capacity, or angiogenic potential, of cardiomyocytes.

Results

PDGFR-β expression in cardiomyocytes increases dramatically in response to pressure overload–induced stress.

We exposed C57BL/6 mice to transverse aortic constriction (TAC), in which a ligature is placed at the aortic arch, resulting in acute pressure overload. As expected, we observed profound increases in cardiac weight (Figure (Figure1A)1A) and cardiac thickness (Figure (Figure1B)1B) in mice exposed to TAC. Cardiac lysates from mice exposed to TAC exhibited increased levels of PDGFR-β persisting to 14 days after TAC (Figure (Figure1C).1C). Quantitative densitometry revealed a 10-fold increase in PDGFR-β protein levels in the heart 7 days after TAC (Figure (Figure1D).1D). Enhanced PDGFR-β expression after TAC was predominantly seen on cardiomyocytes (Figure (Figure1E),1E), as opposed to non-myocyte cells within the heart such as fibroblasts or endothelial cells. A substantial increase in phosphorylated, activated PDGFR-β was seen in the heart 7 days after TAC (Figure (Figure1F)1F) and 14 days after TAC (data not shown), suggesting that changes in PDGFR-β in the cardiomyocyte after TAC were functionally important. Marked increases in levels of phosphorylated Akt and ERK1/2, established downstream effectors of PDGFR-β, were also observed in the heart after TAC. Immunohistochemistry with a phospho-specific PDGFR-β antibody demonstrated that phospho–PDGFR-β after TAC was increased predominantly in cardiomyocytes (Figure (Figure1G).1G). Levels of PDGFR-α were increased in the hearts of mice exposed to TAC compared with sham-operated mice (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI39434DS1), but we observed no increase in phosphorylation of PDGFR-α (data not shown), suggesting a dominant biological role of PDGFR-β compared with PDGFR-α in the heart after exposure to load stress. We also observed significantly increased levels of local expression of the PDGFR-β ligands PDGF-B and PDGF-C 3 days after TAC (Supplemental Figure 2), while levels of PDGF-A and PDGF-D were significantly decreased in the heart 3 days after TAC, suggesting that dynamic changes in local PDGF expression may contribute to activation of PDGFR-β after TAC.

Figure 1
PDGFR-β expression and phosphorylation in cardiomyocytes increase dramatically in response to pressure overload stress.

Cardiomyocyte PDGFR-β is not required for normal cardiac development or basal adult cardiac function.

To further explore the role of PDGFR-β signaling in cardiac function, we constructed mice in which PDGFR-β was knocked out in cardiomyocytes. This was done by crossing mice expressing the Cre recombinase driven by the Nkx2.5 promoter (Nkx2.5-Cre mice) (14) with mice in which PDGFR-β was flanked by loxP sites (Pdgfrbfl/fl mice) (15). Nkx2.5 is a cardiac-specific transcription factor that exhibits expression at high levels in the heart beginning at 9.5 dpc (14). Nkx2.5-Cre:Pdgfrbfl/fl mice (cardiac-specific PDGFR-β–knockout mice; PdgfrbNkx-Cre) were born at the expected Mendelian frequency (data not shown) and were able to support pregnancy. To confirm that the knockout strategy was successful and specific, we isolated genomic DNA from the hearts of newborn PdgfrbNkx-Cre mice. The presence of the lower PCR band represents the Cre-excised allele (Figure (Figure2A),2A), and this was seen in the heart, but not in mouse tails or skeletal muscle, while the higher band, the nonexcised floxed allele, was markedly diminished in the heart compared with other tissues. Furthermore, representative Western blots from hearts of 4-week-old mice demonstrated reduced levels of PDGFR-β protein in PdgfrbNkx-Cre compared with Pdgfrbfl/fl controls (Figure (Figure2B).2B). Analysis of mutant embryos at 15.5 dpc revealed normal cardiac trabeculation and no evidence of septal or outflow tract abnormalities (data not shown), as observed in conventional knockout models of PDGF-B (16) and PDGFR-α (17).

Figure 2
Cardiac-specific PDGFR-β–knockout mice develop ventricular dilatation and heart failure in response to pressure overload.

When animals were 6 weeks of age, we observed no significant difference in cardiac ejection fraction in PdgfrbNkx-Cre compared with Pdgfrbfl/fl or Nkx2.5-Cre control mice (Table (Table1).1). Notably, we did observe a small but significant increase in heart weight/body weight ratio in PdgfrbNkx-Cre compared with Pdgfrbfl/fl or Nkx2.5-Cre control mice, driven largely by nonsignificant increases in the thickness of the intraventricular septum and posterior walls. In addition, we observed small, significant increases in lung weight/body weight ratios in PdgfrbNkx-Cre mice. Importantly, cardiac ejection fractions, heart weights, and ventricular chamber sizes were normal in 8-month-old PdgfrbNkx-Cre mice and were not different from those of Pdgfrbfl/fl or Nkx2.5-Cre controls (data not shown). Thus, cardiomyocyte PDGFR-β signaling does not appear to play a key role in cardiac development or in basal adult cardiac function.

Table 1
Cardiac function and morphometry of 6-week-old cardiac-specific PDGFR-β–knockout mice (PdgfrbNkx-Cre) compared with controls (Nkx2.5-Cre and Pdgfrbfl/fl)

PDGFR-β cardiac-specific knockout mice develop ventricular dilatation and heart failure in response to pressure overload.

To determine whether cardiomyocyte PDGFR-β is a required component of the cardiac response to pressure overload, we exposed 8- to 12-week-old PdgfrbNkx-Cre mice or littermate Pdgfrbfl/fl controls to TAC stress. The ratio of right-to-left carotid flow velocities, a surrogate of the degree of aortic impedance imposed in our TAC model (18), was similar in PdgfrbNkx-Cre mice and Pdgfrbfl/fl controls (Figure (Figure2C).2C). Notably, cardiac ejection fractions in PdgfrbNkx-Cre mice were significantly decreased compared with those in Pdgfrbfl/fl controls at 7 days after TAC, with a further decline 14 days after TAC (Figure (Figure2D).2D). In addition, PdgfrbNkx-Cre mice displayed increased heart weight/body weight ratios 14 days after TAC (Figure (Figure2E),2E), indicative of enhanced pathologic hypertrophy in PdgfrbNkx-Cre mice after TAC stress. Cardiomyocyte cross-sectional area 14 days after TAC was significantly increased in PdgfrbNkx-Cre mice compared with Pdgfrbfl/fl controls (Supplemental Figure 3), further indicative of a pathologic hypertrophy phenotype. Representative short-axis systolic and diastolic still frame MRI images (Figure (Figure2F)2F) demonstrated the acquired cardiac dysfunction seen in PdgfrbNkx-Cre mice 14 days after TAC. Lung weights were significantly increased in PdgfrbNkx-Cre mice 14 days after TAC (Figure (Figure2G),2G), indicative of pulmonary edema and functional heart failure.

Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart failure in response to TAC stress.

Our findings in PdgfrbNkx-Cre mice suggest that PDGFR-β signaling plays a key role in the cardiac response to load stress. However, we could not exclude the possibility that developmental abnormalities and/or expression of Cre recombinase in PdgfrbNkx-Cre mice predispose these mice to cardiac failure upon exposure to TAC. To specifically determine the role of PDGFR-β signaling in the adult cardiac response to load-induced stress, we crossed Pdgfrbfl/fl mice with mice expressing the MerCreMer transgene driven by the α-MHC promoter (MerCreMer mice), which exhibit high cardiac levels of nuclear Cre recombinase activity only in the presence of tamoxifen (19). Hearts from α-MHC-MerCreMer:Pdgfrbfl/fl mice (inducible, cardiac-specific PDGFR-β–knockout mice, PdgfrbMerCre) expressed reduced levels of PDGFR-β (Figure (Figure3A)3A) compared with non–Cre-expressing, tamoxifen-treated Pdgfrbfl/fl controls. We observed no compensatory differences in the expression of PDGFR-α in the hearts of PdgfrbMerCre mice compared with Pdgfrbfl/fl control mice (Supplemental Figure 4). Inducible mutants were exposed to a similar degree of TAC stress as either Pdgfrbfl/fl or MerCreMer control mice (Figure (Figure3B).3B). Heart weights of tamoxifen-treated PdgfrbMerCre mice significantly increased in response to TAC compared with those of tamoxifen-treated Pdgfrbfl/fl or MerCreMer controls (Figure (Figure3C).3C). Cardiomyocyte cross-sectional area 14 days after TAC was significantly increased in PdgfrbMerCre mice compared with Pdgfrbfl/fl and MerCreMer controls (Supplemental Figure 5), further indicative of a pathologic hypertrophy phenotype in PdgfrbMerCre mice. PdgfrbMerCre mice experienced significant declines in cardiac ejection fraction 7 days after TAC and severe cardiac dysfunction 14 days after TAC compared with Pdgfrbfl/fl or MerCreMer controls (Figure (Figure3D).3D). Cardiac dysfunction and pathologic hypertrophy in PdgfrbMerCre mice was associated with increased ventricular dilatation, seen 14 days after TAC in PdgfrbMerCre mice (Figure (Figure3E).3E). Representative hearts from PdgfrbMerCre mice and Pdgfrbfl/fl controls 14 days after TAC demonstrate the observed cardiac dilatation (Figure (Figure3F).3F). MRI cine videos demonstrate the load-induced dilated cardiomyopathy phenotype in PdgfrbMerCre mice (Supplemental Video 1). Significant increases in lung weight, indicative of pulmonary edema, were seen in PdgfrbMerCre mice compared with either MerCreMer or Pdgfrbfl/fl control mice beginning at 7 days after TAC, and differences were even more striking 14 days after TAC (Figure (Figure3G).3G). Expression of B-type natriuretic peptide (BNP), a marker of pathologic hypertrophy and heart failure (20), was increased in hearts of PdgfrbMerCre mice as early as 3 days after exposure to TAC (Figure (Figure3H). 3H).

Figure 3
Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart failure in response to pressure overload.

Inducible cardiac-specific PDGFR-β–knockout mice exhibit impaired activation of Akt and MAPK pathways in the progression to heart failure.

To gain insight into the mechanism of load-induced heart failure in PdgfrbMerCre mice, we measured changes in the PI3K and MAPK pathways, effectors of PDGFR signaling (21) known to mediate the compensatory cardiac response to load-induced stress (22). Levels of phosphorylation of p38 kinase, whose role in cardiac protection is ambiguous (23), were significantly decreased in hearts of PdgfrbMerCre mice at 7 and 14 days after TAC (Figure (Figure4,4, A and B). Phosphorylation of ERK1/2, previously demonstrated to protect the heart in response to load stress (24), was significantly decreased at 14 but not 7 days after TAC in PdgfrbMerCre mice (Figure (Figure4,4, A and C). A similar pattern was observed with respect to phosphorylation of JNK kinase (Figure (Figure4A).4A). In addition, levels of phosphorylation of the protein kinase Akt were significantly reduced in PdgfrbMerCre mice compared with Pdgfrbfl/fl controls 14 days after exposure to TAC (Figure (Figure4,4, D and E).

Figure 4
Inducible, cardiac-specific PDGFR-β–knockout mice exhibit impaired activation of Akt and MAPK pathways in the progression to heart failure.

We also observed diminished phosphorylation of both Akt and ERK1/2 in the hearts of PdgfrbNkx-Cre mice compared with controls 14 days after TAC stress (Supplemental Figure 6). Since both Akt and ERK1/2 exert cardioprotective effects in part via inhibition of apoptosis, we sought to determine whether cardiomyocyte apoptosis after TAC was different in PdgfrbMerCre mice compared with Pdgfrbfl/fl controls. Consistent with our biochemical findings, the number of apoptotic cardiomyocytes was increased in PdgfrbMerCre mice 7 days after TAC and continued to rise 14 days after TAC (Figure (Figure4F).4F). Overall, these findings suggest that PDGFR-β signaling in the heart may participate in modulating the activation of cardioprotective protein kinases in the progression of heart failure due to pressure overload.

Angiogenic gene expression profile correlates with defective microvascular function in inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to load stress.

The majority of the biochemical changes described in Figure Figure44 occurred after the initiation of the heart failure phenotype in PdgfrbMerCre mice upon exposure to pressure overload. To understand the initiating biological mechanism of heart failure in PdgfrbMerCre mice, we focused on identifying biologic changes between PdgfrbMerCre mice and Pdgfrbfl/fl controls at time points preceding the development of overt heart failure using a broad approach, namely microarray gene expression studies. Of the genes that were differentially expressed (Supplemental Table 1), we focused on a group of genes that exhibited the pattern depicted in Figure Figure5A5A — genes expressed in the heart at similar levels in PdgfrbMerCre mice and Pdgfrbfl/fl controls prior to TAC but increased in Pdgfrbfl/fl controls compared with PdgfrbMerCre mice at early time points (3 and 7 days) after TAC. Functional annotation clustering of this subset of genes revealed an enrichment of genes that participate in multiple facets of angiogenesis (Figure (Figure5B),5B), including endothelial cell proliferation (e.g., Agtrl1; ref. 25), endothelial cell migration (Angpt1; ref. 26), extracellular matrix remodeling (e.g., Mmp2; ref. 27), and proangiogenic transcription factors (e.g., Elk3). We thus postulated that PDGFR-β signaling in the cardiomyocyte regulates cardiac angiogenesis in response to stress. This hypothesis correlates with reports indicating that the cardiomyocyte itself is a paracrine cell functioning to enhance blood vessel growth during conditions of increased substrate demand (2830).

Figure 5
Angiogenic gene expression profile correlates with defective microvascular function in inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to load stress.

To test this hypothesis, we measured coronary flow reserve (CFR), which provides a robust assessment of coronary microvascular function in mice (31) and humans (32). Representative tracings (Figure (Figure5C)5C) of coronary flow in response to vasodilator stimulus (2.5% inhaled isoflurane; ref. 33) demonstrate reduced hyperemic coronary flow in PdgfrbMerCre mice at baseline and after TAC. Quantification of CFR demonstrated a significant reduction at baseline in PdgfrbMerCre mice compared with either MerCreMer or Pdgfrbfl/fl controls (Figure (Figure5D).5D). By 7 days after TAC, PdgfrbMerCre mice had minimal augmentation of coronary flow in response to vasodilator stimulus (CFR = 1), suggestive of a severe coronary microvascular defect. To determine whether PdgfrbMerCre mice had a global decline in myocardial perfusion in response to TAC, we used a microbubble perfusion method, producing a contrast-enhanced ultrasound signal in the myocardium that is directly proportional to perfusion (34). Using this technique throughout all assessable portions of the heart (the anterior and lateral segments of the left ventricle), we observed a reduction in myocardial perfusion in PdgfrbMerCre mice compared with Pdgfrbfl/fl controls (Figure (Figure5E).5E). Overall myocardial perfusion was reduced by 24.6% in inducible-mutant mice compared with controls 14 days after TAC (n = 3 PdgfrbMerCre mice, n = 4 Pdgfrbfl/fl mice, P = 0.01).

Impaired angiogenesis and evidence of ischemic injury in the hearts of inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to load stress.

Recent work demonstrates that angiogenesis is a crucial adaptive mechanism accompanying cardiac hypertrophy and manifesting as an increased number of coronary microvessels per cardiomyocyte (29). To determine whether coronary angiogenesis in response to pressure overload was impaired in PdgfrbMerCre mice, we quantified coronary microvessels at baseline or after TAC exposure. The number of CD31 microvessels per myocyte at baseline was not different in the hearts of PdgfrbMerCre mice compared with Pdgfrbfl/fl controls (Figure (Figure6A).6A). In contrast, while Pdgfrbfl/fl and MerCreMer control mice had a rise in coronary microvessels per cardiomyocyte in response to TAC consistent with previous findings (29), this increase was significantly blunted in PdgfrbMerCre mice at 7 and 14 days after TAC. Representative photomicrographs from hearts 14 days after TAC demonstrate the reduction in microvascular density in hearts of PdgfrbMerCre mice compared with MerCreMer or Pdgfrbfl/fl controls (Figure (Figure6B). 6B).

Figure 6
Impaired angiogenesis and evidence of ischemic injury in the hearts of inducible, cardiac-specific PDGFR-β–knockout mice upon exposure to load stress.

Histologically, hearts from PdgfrbMerCre mice demonstrated a significant increase in fibrosis (Figure (Figure6C)6C) distributed throughout the subendocardium, the portion of the heart most susceptible to ischemic injury. To determine whether the reduction in angiogenesis resulted in functional myocardial ischemia, we used 2-nitroimidazole, an immunochemical marker for cardiac hypoxia (29). We observed a significant increase in myocardial hypoxia in PdgfrbMerCre mice 7 days after TAC (Figure (Figure6E)6E) and a more dramatic increase in hypoxia in the hearts of PdgfrbMerCre mice 14 days after TAC, visually demonstrated in Figure Figure6D.6D. Biochemically, we observed increased levels of the transcription factor HIF-1α, whose expression increases in the ischemic heart (35), 7 days after TAC in PdgfrbMerCre mice compared with Pdgfrbfl/fl controls (Supplemental Figure 7), along with increased levels of the HIF-1α–dependent factor VEGF-A. However, 14 days after TAC, both HIF-1α and VEGF-A levels were significantly reduced in the hearts of PdgfrbMerCre mice despite profound tissue hypoxia. Taken together, our findings demonstrate that loss of cardiomyocyte PDGFR-β signaling results in a functional and structural defect in coronary microvascular flow accompanied by evidence of global myocardial ischemia in response to pressure overload–induced stress.

Cardiomyocyte PDGFR-β is an essential regulator of the paracrine angiogenic capacity of cardiomyocytes.

Our in vivo observations demonstrate that loss of cardiomyocyte PDGFR-β results in load-induced cardiac dysfunction associated with impairment in cardiac angiogenesis. Based upon our gene expression data (Figure (Figure5,5, A and B), we hypothesized that PDGFR-β is a regulator of the paracrine angiogenic capacity, or angiogenic potential, of cardiomyocytes. To test this hypothesis, we isolated a highly purified population of neonatal cardiomyocytes from Pdgfrbfl/fl mice (Figure (Figure7A).7A). In vitro infection of these cardiomyocytes with Ad-Cre, but not with Ad-GFP, resulted in deletion of the floxed allele, detectable by PCR of genomic DNA (Figure (Figure7B).7B). Cre-mediated deletion of the floxed PDGFR-β allele from isolated cardiomyocytes resulted in a marked decrease in mRNA encoding PDGFR-β (Figure (Figure7C). 7C).

Figure 7
Cardiomyocyte PDGFR-β is an upstream regulator of the paracrine angiogenic capacity of cardiomyocytes.

Using this primary cardiomyocyte model, we first explored the ability of PDGF stimulation to enhance the ability of cardiomyocytes to support angiogenesis. In experiments in which cardiomyocytes from Pdgfrbfl/fl mice were used, conditioned media from control, noninfected cardiomyocytes, Ad-GFP–infected cardiomyocytes, or Ad-Cre cardiomyocytes was harvested before and after treatment with PDGF-BB or vehicle control. Conditioned media from control or Ad-GFP cardiomyocytes demonstrated a marked increase in the capacity to promote endothelial tube formation (a surrogate assay to assess the angiogenic capacity of cardiomyocytes) after treatment with PDGF-BB (Figure (Figure7D),7D), an effect not directly attributable to PDGF-BB (see Media, white bars). In contrast, the angiogenic capacity of conditioned media from cardiomyocytes in which PDGFR-β was deleted by Ad-Cre infection was not enhanced by PDGF-BB treatment. These findings demonstrate that PDGF-BB potently enhances the paracrine angiogenic capacity of cardiomyocytes in a PDGFR-β–dependent manner.

To determine whether PDGFR-β is a required component of the angiogenic potential of cardiomyocytes under conditions of physiologic stress, we exposed control, Ad-GFP–infected, or Ad-Cre–infected neonatal cardiomyocytes from Pdgfrbfl/fl mice to hypoxia, then harvested the conditioned media from these myocytes and tested its ability to support endothelial tube formation. Hypoxia significantly increased the capacity of conditioned media from control and Ad-GFP cardiomyocytes to support tube formation (Figure (Figure7E).7E). In contrast, we saw a reduction in the angiogenic capacity of conditioned media from Ad-Cre–infected, PDGFR-β–deleted cardiomyocytes upon exposure to hypoxic stress. To determine whether Ad-Cre infection had a direct toxic effect on the angiogenic capacity of cardiomyocytes, we infected control neonatal cardiomyocytes (not bearing the PDGFR-β floxed allele) with Ad-Cre or Ad-GFP and exposed these myocytes to hypoxia. As shown in Figure Figure7F,7F, Ad-Cre infection had no effect on the paracrine ability of cardiomyocytes to support endothelial tube formation in response to hypoxia. As an independent measure of the PDGFR-β–dependent paracrine angiogenic capacity of cardiomyocytes, we found that conditioned media from Ad-Cre–infected cardiomyocytes from Pdgfrbfl/fl mice exposed to hypoxia had an impairment in the ability to support in vitro endothelial cell proliferation compared with Ad-GFP or control cardiomyocytes (Figure (Figure7G).7G). Experiments using wild-type cardiomyocytes demonstrated that this impairment in promoting endothelial cell proliferation is not attributable to Ad-Cre infection (Figure (Figure7G).7G). Furthermore, we identified a series of factors known to enhance in vivo angiogenesis that demonstrated a trend toward reduced expression in Ad-Cre–infected, PDGFR-β–deficient cardiomyocytes compared with control, Ad-GFP–infected cardiomyocytes after both cell models were exposed to hypoxia in vitro (Figure (Figure7H),7H), including statistically significant reductions in expression of Cxcl1, Cxcl2, and Fgf1. Thus, our findings demonstrate that PDGFR-β is an essential regulator of the angiogenic capacity of cardiomyocytes in response to hypoxic stress, in part through regulation of a program of expression of angiogenic factors. These findings are consistent with and provide a direct mechanistic basis for the cardiac dysfunction and impairment of load stress–induced angiogenesis observed in cardiac-specific PDGFR-β–knockout mice.

Discussion

We show here that PDGFR-β is an indispensable component of the cardiac response to pressure overload–induced stress. The robustness of our findings is reflected in the similarity of phenotype in 2 independent but overlapping knockout systems. Mechanistically, our findings suggest that PDGFR-β signaling is an important upstream regulator of the angiogenic potential of the cardiomyocyte in response to stress. The notion that PDGFR signaling regulates proangiogenic pathways has precedent in other systems. For example, PDGFR signaling in tumor-associated stromal cells exerts a proangiogenic effect in the tumor microenvironment (36). Furthermore, a recent report revealed that knockout of PDGFR-β in the epicardium inhibits normal development of epicardial coronary arteries (37).

PDGFR-β signaling in the cardiomyocyte may regulate angiogenesis in the heart in response to load-induced stress through several different mechanisms. Recent work has demonstrated that activation of the PI3K and MAPK pathways enhance the angiogenic capacity of cardiomyocytes via a HIF-1α/VEGF-A–dependent mechanism (30). Intriguingly, we observed an increase in levels of phosphorylated Akt and a decrease in levels of phosphorylated p38 in the hearts of PdgfrbMerCre mice prior to TAC compared with levels in hearts of Pdgfrbfl/fl mice (Figure (Figure4),4), although these changes did not achieve statistical significance when quantified by densitometry. Furthermore, we observed significantly decreased phosphorylation of Akt, p38, and ERK1/2 together with significantly decreased expression of HIF-1α and VEGF-A in PdgfrbMerCre mice 14 days after exposure to TAC stress. However, at earlier time points after TAC (day 7), expression of both HIF-1α and VEGF-A were increased in PdgfrbMerCre mice exposed to TAC compared with Pdgfrbfl/fl control mice. By this time point, PdgfrbMerCre mice already exhibited cardiac dysfunction along with markedly reduced numbers of blood vessels per cardiomyocyte and functional hypoxia. These observations suggest that the PDGFR-β–dependent angiogenic capacity of cardiomyocytes is independent of HIF-1α/VEGF-A expression. Elucidation of the signaling pathways downstream of PDGFR-β that are essential regulators of the PDGFR-β–dependent angiogenic capacity of cardiomyocytes is a goal of our future studies, as is the determination of the precise identity of paracrine factors that mediate the PDGFR-β–dependent paracrine angiogenic capacity of cardiomyocytes. Importantly, cardiomyocyte PDGFR-β signaling may regulate aspects of the cardiac response to pressure overload other than angiogenesis (e.g., substrate utilization) that substantially contribute to heart failure in cardiac-specific PDGFR-β–knockout mice, which we will explore in future studies.

Our findings suggest that therapeutics that augment cardiomyocyte PDGFR signaling in the heart may be a novel strategy for the treatment of cardiac disease in which defective angiogenesis is a contributor to disease pathogenesis. Consistent with this hypothesis are prior studies that demonstrate that administration of PDGF-BB prevents adverse remodeling after experimental myocardial infarction (38, 39). More generally, our findings support the general notion that targeting cardiac angiogenesis through the PDGF/PDGFR system or via other means may be an effective approach to prevent the progression of multiple forms of heart failure (40), including “nonischemic” cardiomyopathies, in which functional and structural microvascular abnormalities are well described (41).

Our studies were inspired by observations of cardiac toxicity in cancer patients treated with PDGFR inhibitors. Our results provide a mechanistic rationale to aggressively treat hypertension and thus minimize vascular stress as a strategy to prevent heart failure due to anticancer PDGFR inhibitors. Based on our findings, we also speculate that patients with preexisting coronary disease at the macro- or microvascular level may be at increased risk for cardiomyopathy and heart failure associated with these drugs. Confirmation of such findings could provide the basis for a risk stratification tool in cancer patients being considered for treatment with PDGFR inhibitors and could be used to develop strategies to prevent adverse cardiac effects of PDGFR inhibitors.

It is important to note that targets other than PDGFR may be involved in cardiotoxicity due to anticancer PDGFR inhibitors. Both sunitinib and sorafenib can exert substantial off-target effects on other kinases (42), and these can be independent or additive to their effects on cardiomyocyte PDGFR signaling that result in clinical heart failure. Furthermore, cardiotoxicity due to imatinib has been demonstrated to involve Abl kinase (11, 43), while the role of PDGFR signaling in cardiotoxicity due to imatinib is unclear (44). Fundamentally, it is of critical importance to determine the contribution of the inhibitory effects on PDGFR to the clinical cardiac toxicity observed with RTK inhibitors whose targets include PDGFR. Such information will be useful to achieve the goal of designing highly efficacious, novel anticancer agents with minimal cardiotoxicity.

Finally, our studies highlight the opportunities for discovery that can be capitalized upon based upon cardiac toxicity of novel, targeted anticancer agents. Such toxicities may reveal biological pathways whose role in the regulation of cardiovascular physiology were previously unknown, and detailed exploration of such pathways may be useful for developing new, effective treatments for multiple forms of human heart failure.

Methods

Developmental, cardiac-specific PDGFR-β–knockout mice.

Mice expressing Cre recombinase driven by the Nkx2.5 promoter (C57BL/6 background) were crossed with Pdgfrbfl/fl mice (129 background) to create Nkx2.5-Cre:Pdgfrbfl/fl (PdgfrbNkx-Cre) mice or littermate control, non–Cre-expressing Pdgfrbfl/fl mice (mixed C57BL/6 × 129 background). To study the effects of the Nkx2.5-Cre transgene on basal cardiac function in an identical genetic background, we crossed mice expressing Cre recombinase driven by the Nkx2.5 promoter (C57BL/6 background) with wild-type 129 mice to generate Nkx2.5-Cre mice in a mixed C57BL/6 × 129 background. Nkx2.5-Cre mice were provided by R.J. Schwartz (Institute of Biosciences and Technology, Houston, Texas, USA). Pdgfrbfl/fl mice were provided by P. Soriano (Mount Sinai School of Medicine, New York, New York, USA).

Inducible, cardiac-specific Pdgfrb-knockout mice.

To create inducible, cardiac-specific PDGFR-β–knockout mice, we crossed heterozygous α-MHC-MerCreMer mice (C57BL/6 background) with Pdgfrbfl/fl mice (129 background), resulting in Pdgfrbfl/fl mice and α-MHC-MerCreMer:Pdgfrbfl/fl (PdgfrbMerCre) mice in a mixed C57BL/6 × 129 background. To study any possible contribution of the α-MHC-MerCreMer transgene, we used heterozygous α-MHC-MerCreMer mice in a similar, mixed C57BL/6 × 129 background. All groups were treated with 4-hydroxytamoxifen beginning at age 6–8 weeks. 4-Hydroxytamoxifen was administered intraperitoneally at a dosage of 20 mg/kg/d for a total of 5 days. Mice were given 7–10 days of rest after the last dosage of 4-hydroxytamoxifen prior to functional characterization or to exposure to pressure overload–induced stress induced by TAC.

TAC.

The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee approved all animal protocols used in this study. Eight- to 12-week-old male mice were used for functional experiments. TAC surgeries were performed based on previously described protocols (45). The sham procedure was similar, except that the aorta was not ligated.

Ultrasound measurement of aortic, carotid, and coronary flows.

Carotid velocities were measured 24 hours, 7 days, and 14 days after TAC using a 20-Mhz ultrasound probe connected to a signal processing unit (Indus Instruments) using our previously published protocol (46). CFR was measured as previously described (33). Briefly, the ultrasound probe tip was placed at the left side of the chest of the anesthetized animal and stabilized using a micromanipulator (model MM3-3, World Precision Instruments). Peak coronary velocities were identified, and the probe was fixed in position. Baseline coronary flow was measured at 1.0% isoflurane. As a coronary vasodilator stimulus, the inhaled isoflurane concentration was increased to 2.5%. The coronary vasodilatory properties of isoflurane in general are well described (47), and we have previously validated its use in the measurement of CFR in conjunction with a noninvasive ultrasound technique (33, 48). Ratios of peak velocities at low- (1%) and high-dose (2.5%) isoflurane were reported as CFR.

In vivo myocardial perfusion studies.

For myocardial perfusion studies, short- and long-axis echocardiographic images were obtained using the Vevo 770 machine (Visual Sonics). Baseline short-axis images were obtained, followed by injection of a 50-μl bolus containing 1.2 × 107 DEPO Micromarker microbubbles (Visual Sonics) via tail vein. After 12–15 minutes of contrast agent bolus injection, short-axis images were again captured without moving the probe. Global perfusion was only assessable in the anterior and lateral portions of the left ventricle, due to shadowing cast on the septum and posterior aspect of the heart, rendering this data uninterpretable. Quantification of overall perfusion was performed by integrating contrast values obtained from 9 separate measurements from each of at least 3 mice in each group.

Cardiac MRI.

Cardiac function in experimental mice was measured by magnetic resonance (MR) scanning using a retrospectively gated imaging method (49). MR scanning experiments were performed using a Bruker 7T MR scanner (BioSpin MRI). Mice were anesthetized using 1%–3% isoflurane in oxygen, and 0.5%–1.5% isoflurane was delivered to maintain anesthesia. During MR scanning, heart rates and respiratory rates were 350–500 beats/minute and 25–40/minute, respectively. Each MR scan included a scout; single-slice sagittal and coronal long-axis cine images of the heart; and a series of axial short-axis cine acquisitions. Sagittal and coronal images were used to establish the cardiac axis and to identify the apex for prescribing short-axis cine slices. Short-axis cine images were used to quantify LV end-diastolic and -systolic volumes. LV volumes, anterior and posterior wall thickness, and LV internal diameter at different phases of the cardiac cycle were measured using ParaVision software (Bruker BioSpin). The total cross-sectional area in the 1-mm-thick short-axis slices (typically 6–8 slices) from apex to base was integrated to calculate ventricular volumes and ejection fractions.

Tissue preparation.

We used a previously published method adopted to arrest hearts of inducible mutant mice or controls in diastole and fix them in 10% formalin (50). Five-micrometer sections of formalin-fixed, paraffin-embedded tissue were used for TUNEL assay, H&E staining, Masson’s trichrome staining, and immunohistochemistry.

Myocyte cross-sectional area.

Horizontal short-axis cut hearts were fixed in 10% buffered formalin solution for 24 hours. Paraffin-embedded hearts were sectioned at 5-mM thickness. All the sections were stained according to previously standard methods. Briefly, sections were deparaffinized, rehydrated, and then incubated for 1 hour with TRITC-labeled lectin (100 μg/ml; Sigma-Aldrich). Multiple ×400 magnified pictures were captured using a fluorescence microscope (Olympus BX41) from epicardial and endocardial areas of the left ventricle. Myocytes (40–60/heart) that showed round capillaries and clear membrane staining were included in the analysis. The Scion Image (Scion Corp.) program was used to calculate cross-sectional area.

Measurement of microvascular density.

We used an antibody directed against CD31 (BD Biosciences) to stain cardiac microvessels. Detection, staining, and counterstaining with hematoxylin was performed using standard methods. For quantification of microvessels, at least 3 random fields (×400) from each of 2 independent sections for each heart assessed were analyzed. To normalize microvessel density to the number of cardiomyocytes present, the same images used to quantify microvessel number were used to count cardiomyocyte nuclei, which were identified based upon their morphologic appearance made visible by counterstaining.

TUNEL assay.

TUNEL staining was performed on formalin-fixed, paraffin-embedded tissue using the In Situ Cell Death Detection Kit (Roche Applied Science). Sections were counterstained with DAPI, and apoptotic cells per 105 cardiomyocytes were quantified using previously described methods (51).

Tissue hypoxia measurement.

To analyze tissue hypoxia 7 and 14 days after TAC, we treated all mice intraperitoneally with 60 mg/kg pimonidazole hydrochloride (Hypoxyprobe, Natural Pharmacia International) 3 hours prior to sacrifice. Immunodetection of Hypoxyprobe binding, indicative of tissue hypoxia, was performed using a previously described method (52). For quantification of cardiac hypoxic area, at least 6 high-magnification (×400) randomly chosen fields from the left ventricle were selected for quantification of immunopositive cells, and the average number of positive staining cells per field was used as an index of tissue hypoxia. Quantification of hypoxic area in hearts of inducible mutant or control mice after TAC was performed by an investigator blinded to the sample identification, using NIH ImageJ software (http://rsbweb.nih.gov/ij/) incorporating standard, grid-based quantitative morphometric techniques (53). For determination of statistical significance between groups at each day, we fit a mixed-effects linear model, with genotype as the fixed effect and animal as the random effect. We used an F-test to determine the significance of differences between genotypes.

Quantitative densitometry.

Primary antibodies from Cell Signaling Technology were directed at the following antigens: Akt, phospho-Akt (Ser473), ERK1/2, phospho-ERK1/2 (Thr202/Tyr204), PDGFR-β, JNK, phospho-JNK (Thr183/Tyr185), p38, and phospho-p38 (Thr180/Tyr182). Primary antibodies obtained from Santa Cruz Biotechnology Inc. were directed at the following antigens: VEGF-A, GAPDH, GATA4, and phospho–PDGFR-β (Tyr 1021). Anti–HIF-1α antibody was obtained from Novus Biologicals. Protein bands were quantified via densitometry using Fluorchem 8900 imaging software (Alpha Innotech).

RNA isolation for quantitative RT-PCR and gene expression microarrays.

Total RNA was isolated from heart tissues using TRIzol (Invitrogen) reagent using the manufacturer’s recommended protocol. RNA integrity was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies), with samples run against an RNA ladder of specified molecular weights (Eukaryote Total RNA Nano Series II, Agilent Technologies).

Gene expression microarrays.

Mouse genome 430 2.0 array gene chips were purchased from Affymetrix and probed with RNA according to the manufacturer’s recommended protocol using a double in vitro transcription method, and data were processed for analysis as previously described (54).

Genotyping by PCR.

Genomic DNA was extracted from mouse tails with the RedExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich). Primers were as follows: Nkx2.5-Cre forward, 5′-GGCGTTTTCTGAGCATACCT-3′, and Nkx2.5-Cre reverse, 5′-CTACACCAGAGACGGAAATCCA-3′; internal control forward, 5′-CTAGGCCACAATTGAAAGATCT-3′, and internal control reverse, 5′-GTAGGTGGAAATTCTAGCATCATCC-3′; MerCreMer forward, 5′-ATACCGGAGATCATGCAAGC-3′, and MerCreMer reverse, 5′-AGGTGGACCTGATCATGGGAG-3′; internal control forward, 5′-CTAGGCCACAATTGAAAGATCT-3′, and internal control reverse, 5′-GTAGGTGGAAATTCTAGCATCATCC-3′. To check for the Pdgfrb floxed/deleted allele, the forward primer was 5′-GGAAAAGCAGGTTTGTGC-3′, the floxed reverse primer was 5′-TACCAGGAAGGCTTGGGAAG-3′, and the deleted allele reverse primer was 5′-CCAGTTAGTCCACCTATGTTG-3′.

Neonatal murine cardiomyocyte isolation, adenoviral infection, and hypoxia.

Neonatal mouse cardiomyocytes were isolated using a commercially available kit from Cellutron (55). Briefly, hearts from 2- to 3-day-old wild-type or Pdgfrbfl/fl mice were removed and incubated with digestion medium and then centrifuged to collect the dissociated cells from the medium. Cell cultures were at least 95% pure of cardiomyocytes as determined by flow cytometry after immunostaining of cardiac myosin, a marker of cardiomyocytes. Cells were infected with 25 MOI of adenoviral CMV-GFP or adenoviral CMV-CreGFP (gifts of M.D. Schneider, Imperial College, London, United Kingdom) in growth medium for 48 hours, and then cells were incubated at 37°C with serum-free DMEM F12 (Invitrogen) for 16–24 hours. After 16 hours exposure of cells to hypoxia (1% O2, 5% CO2, at 37°C) or normoxia (21% O2, 5% CO2, at 37°C), condition medium was collected and stored at –80°C. Cells were collected in TRIzol reagent for RNA isolation.

Endothelial cell proliferation and tube formation assays.

HUVECs were cultured in growth medium (5,000 cells/well of 96-well plate). After 3 hours of incubation, growth medium was replaced with condition medium and then incubated for 24 hours. Cells were counted using a Coulter Z series device. The in vitro angiogenesis assay kit was purchased from Millipore, and the assay method was adapted from previous reports (56). Briefly, HUVECs were cultured using endothelial growth medium for 12 hours. HUVECs (5 × 103/well of a 96-well plate) were resuspended in 150 μl condition medium (from 16-hour hypoxia or normoxia) supplemented with 2% heat-inactivated FBS. Resuspended cells were seeded onto the surface of the ECM-coated wells. After 4–8 hours incubation, 3–5 random view fields (×40 magnified) were pictured for each well. Tube length was calculated using ImageJ software.

Statistics.

In all figures and within the text, data are presented as mean ± SEM. We tested the data for normality using the Kolmogorov-Smirnov test. To assess statistical significance between groups, we used the unpaired 2-tailed Student’s t test or, when appropriate, we used the nonparametric, 2-sided Wilcoxon rank-sum test. A P value less than 0.05 was considered statistically significant. Changes between multiple groups were calculated using ANOVA, and Tukey’s test was then used to test for significant changes between individual groups.

For identification of genes of interest between mutant and control mice over time after TAC using gene expression microarrays, we fit an ANOVA model that accounts for differences due to genotype differences between the 3 time points (day 0, 3, or 7), as well as potential interactions between genotype and day. We used a false discovery rate of 1% to identify genes of interest using this method. To better understand the behavior of the genes found to be differentially expressed by the model (with interaction between treatment and day), we used clustering to group these genes into sets that exhibited similar expression patterns. Gene annotation enrichment analysis of clustered genes was performed using the NIH DAVID annotation tool (http://david.abcc.ncifcrf.gov).

Supplementary Material

Supplemental data:
Supplemental video:

Acknowledgments

We thank T. Finkel (NIH), E.T.H. Yeh (University of Texas MD Anderson Cancer Center), and R. Schwartz (Texas A&M University) for helpful discussions. This work was supported in part by a Howard Hughes Medical Institute Physician-Scientist Early Career Award (to A.Y. Khakoo), a Physician-Scientist Award from the University of Texas MD Anderson Cancer Center (to A.Y. Khakoo), a Michael and Marriet Cyrus Scholar Award (to A.Y. Khakoo), a postdoctoral fellowship from the American Heart Association (to D. Ai), the NIH (HL076661, HL089792, AG17899 to M.L. Entman), and by the Wanamacker Foundation (to M.L. Entman).

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2010;120(2):472–484. doi:10.1172/JCI39434.

References

1. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res. 2004;10(3):897–908. doi: 10.1158/1078-0432.CCR-1151-3. [PubMed] [Cross Ref]
2. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 2001;80:1–38. [PubMed]
3. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol. 1993;143(5):1377–1388. [PMC free article] [PubMed]
4. Uehara H, et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. . J Natl Cancer Inst. 2003;95(6):458–470. [PubMed]
5. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134. doi: 10.1056/NEJMoa060655. [PubMed] [Cross Ref]
6. Peggs K, Mackinnon S. Imatinib mesylate — the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348(11):1048–1050. doi: 10.1056/NEJMe030009. [PubMed] [Cross Ref]
7. Motzer RJ, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–2524. doi: 10.1001/jama.295.21.2516. [PubMed] [Cross Ref]
8. Chu TF, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–2019. doi: 10.1016/S0140-6736(07)61865-0. [PMC free article] [PubMed] [Cross Ref]
9. Khakoo AY, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500–2508. doi: 10.1002/cncr.23460. [PubMed] [Cross Ref]
10. Schmidinger M, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–5212. doi: 10.1200/JCO.2007.15.6331. [PubMed] [Cross Ref]
11. Kerkela R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–916. doi: 10.1038/nm1446. [PubMed] [Cross Ref]
12. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–1237. doi: 10.1182/blood-2007-01-070144. [PubMed] [Cross Ref]
13. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–123. doi: 10.1016/S1470-2045(08)70003-2. [PubMed] [Cross Ref]
14. Moses KA, DeMayo F, Braun RM, Reecy JL, Schwartz RJ. Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. Genesis. 2001;31(4):176–180. doi: 10.1002/gene.10022. [PubMed] [Cross Ref]
15. Schmahl J, Rizzolo K, Soriano P. The PDGF signaling pathway controls multiple steroid-producing lineages. Genes Dev. 2008;22(23):3255–3267. doi: 10.1101/gad.1723908. [PMC free article] [PubMed] [Cross Ref]
16. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994;8(16):1875–1887. doi: 10.1101/gad.8.16.1875. [PubMed] [Cross Ref]
17. Price RL, Thielen TE, Borg TK, Terracio L. Cardiac defects associated with the absence of the platelet-derived growth factor alpha receptor in the patch mouse. Microsc Microanal. 2001;7(1):56–65. [PubMed]
18. Zhang YM, et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 2006;20(7):916–925. doi: 10.1096/fj.05-5129com. [PubMed] [Cross Ref]
19. Sohal DS, et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001;89(1):20–25. doi: 10.1161/hh1301.092687. [PubMed] [Cross Ref]
20. He Q, Wang D, Yang XP, Carretero OA, LaPointe MC. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. Am J Physiol Heart Circ Physiol. 2001;280(1):H368–H376. [PubMed]
21. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998;1378(1):F79–F113. [PubMed]
22. Dorn GW, II, Force Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115(3):527–537. [PMC free article] [PubMed]
23. Bassi R, Heads R, Marber MS, Clark JE. Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol. 2008;8(2):141–146. doi: 10.1016/j.coph.2008.01.002. [PubMed] [Cross Ref]
24. Purcell NH, et al. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A. 2007;104(35):14074–14079. doi: 10.1073/pnas.0610906104. [PMC free article] [PubMed] [Cross Ref]
25. Eyries M, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103(4):432–440. doi: 10.1161/CIRCRESAHA.108.179333. [PubMed] [Cross Ref]
26. Chen JX, Zeng H, Lawrence ML, Blackwell TS, Meyrick B. Angiopoietin-1-induced angiogenesis is modulated by endothelial NADPH oxidase. Am J Physiol Heart Circ Physiol. 2006;291(4):H1563–H1572. doi: 10.1152/ajpheart.01081.2005. [PubMed] [Cross Ref]
27. van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res. 2008;78(2):203–212. doi: 10.1093/cvr/cvm102. [PubMed] [Cross Ref]
28. Heineke J, et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest. 2007;117(11):3198–3210. doi: 10.1172/JCI32573. [PMC free article] [PubMed] [Cross Ref]
29. Sano M, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444–448. doi: 10.1038/nature05602. [PubMed] [Cross Ref]
30. Walsh K, Shiojima I. Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest. 2007;117(11):3176–3179. doi: 10.1172/JCI34126. [PMC free article] [PubMed] [Cross Ref]
31. Saraste A, Kyto V, Saraste M, Vuorinen T, Hartiala J, Saukko P. Coronary flow reserve and heart failure in experimental coxsackievirus myocarditis. A transthoracic Doppler echocardiography study. Am J Physiol Heart Circ Physiol. 2006;291(2):H871–H875. doi: 10.1152/ajpheart.01375.2005. [PubMed] [Cross Ref]
32. Lucarini AR, Picano E, Salvetti A. Coronary microvascular disease in hypertensives. Clin Exp Hypertens A. 1992;14(1–2):55–66. [PubMed]
33. Hartley CJ, et al. Doppler estimation of reduced coronary flow reserve in mice with pressure overload cardiac hypertrophy. Ultrasound Med Biol. 2008;34(6):892–901. doi: 10.1016/j.ultrasmedbio.2007.11.019. [PMC free article] [PubMed] [Cross Ref]
34. Kaufmann BA, et al. High-resolution myocardial perfusion imaging in mice with high-frequency echocardiographic detection of a depot contrast agent. J Am Soc Echocardiogr. 2007;20(2):136–143. [PubMed]
35. Choi YH, et al. Myocardial hypertrophy overrides the angiogenic response to hypoxia. PLoS ONE. 2008;3(12):e4042. doi: 10.1371/journal.pone.0004042. [PMC free article] [PubMed] [Cross Ref]
36. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008;5(1):e19. doi: 10.1371/journal.pmed.0050019. [PMC free article] [PubMed] [Cross Ref]
37. Mellgren AM, et al. Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ Res. 2008;103(12):1393–1401. doi: 10.1161/CIRCRESAHA.108.176768. [PMC free article] [PubMed] [Cross Ref]
38. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(1):237–248. doi: 10.1172/JCI25878. [PMC free article] [PubMed] [Cross Ref]
39. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation. 2006;114(7):637–644. doi: 10.1161/CIRCULATIONAHA.106.639831. [PubMed] [Cross Ref]
40. Gavin JB, Maxwell L, Edgar SG. Microvascular involvement in cardiac pathology. J Mol Cell Cardiol. 1998;30(12):2531–2540. doi: 10.1006/jmcc.1998.0824. [PubMed] [Cross Ref]
41. Tsagalou EP, et al. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2008;52(17):1391–1398. doi: 10.1016/j.jacc.2008.05.064. [PubMed] [Cross Ref]
42. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–344. doi: 10.1038/nrc2106. [PubMed] [Cross Ref]
43. Demetri GD. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest. 2007;117(12):3650–3653. doi: 10.1172/JCI34252. [PMC free article] [PubMed] [Cross Ref]
44. Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2009;23(1):97–107, viii–ix. [PubMed]
45. Li YH, et al. Effect of age on peripheral vascular response to transverse aortic banding in mice. . J Gerontol A Biol Sci Med Sci. 2003;58(10):B895–B899. [PubMed]
46. Li YH, Reddy AK, Taffet GE, Michael LH, Entman ML, Hartley CJ. Doppler evaluation of peripheral vascular adaptations to transverse aortic banding in mice. Ultrasound Med Biol. 2003;29(9):1281–1289. doi: 10.1016/S0301-5629(03)00986-4. [PubMed] [Cross Ref]
47. Zhou X, Abboud W, Manabat NC, Salem MR, Crystal GJ. Isoflurane-induced dilation of porcine coronary arterioles is mediated by ATP-sensitive potassium channels. Anesthesiology. 1998;89(1):182–189. doi: 10.1097/00000542-199807000-00025. [PubMed] [Cross Ref]
48. Hartley CJ, et al. Effects of isoflurane on coronary blood flow velocity in young, old and ApoE(–/–) mice measured by Doppler ultrasound. Ultrasound Med Biol. 2007;33(4):512–521. doi: 10.1016/j.ultrasmedbio.2006.11.002. [PMC free article] [PubMed] [Cross Ref]
49. Crowe ME, et al. Automated rectilinear self-gated cardiac cine imaging. Magn Reson Med. 2004;52(4):782–788. doi: 10.1002/mrm.20212. [PubMed] [Cross Ref]
50. Michael LH, et al. Myocardial infarction and remodeling in mice: effect of reperfusion. Am J Physiol. 1999;277(2 Pt 2):H660–H668. [PubMed]
51. Chang J, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci U S A. 2006;103(39):14495–14500. doi: 10.1073/pnas.0601911103. [PMC free article] [PubMed] [Cross Ref]
52. Kleiter MM, et al. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys. 2006;64(2):592–602. [PubMed]
53. Mouton PR.Principles and Practices of Unbiased Stereology: An Introduction for Bioscientists . Baltimore, MD: Johns Hopkins University Press; 2002.
54. Gold D, et al. A comparative analysis of data generated using two different target preparation methods for hybridization to high-density oligonucleotide microarrays. BMC Genomics. 2004;5(1):2. doi: 10.1186/1471-2164-5-2. [PMC free article] [PubMed] [Cross Ref]
55. Vallentin A, Mochly-Rosen D. RBCK1, a protein kinase CβI (PKCβI)-interacting protein, regulates PKCβ-dependent function. J Biol Chem. 2007;282(3):1650–1657. doi: 10.1074/jbc.M601710200. [PubMed] [Cross Ref]
56. Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res. 2007;74(1):140–150. doi: 10.1016/j.cardiores.2007.01.010. [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...